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Objectives The authors investigated predictors of left ventricular ejection fraction (LVEF) super-response to cardiac resyn-
chronization therapy with defibrillator (CRT-D) and whether super-response translated into improved event-free
survival in patients with mildly symptomatic heart failure (HF).
Background Few data exist on predictors of super-response to CRT-D and associated morbidity and mortality in mildly symp-
tomatic HF populations.
Methods Patients were assigned to CRT-D with paired echocardiograms at baseline and at 12 months (n  752). Super-
response was defined by the top quartile of LVEF change. Best-subset regression analysis identified predictors of
LVEF super-response. Kaplan-Meier survival analysis and Cox proportional hazards regression were performed to
investigate associations of response category with development of nonfatal HF event or all-cause death.
Results All 191 super-responders experienced an LVEF increase of 14.5% (mean LVEF increase 17.5  2.7%). Six pre-
dictors were associated with LVEF super-response to CRT-D therapy: female sex (odds ratio [OR]: 1.96;
p  0.001), no prior myocardial infarction (OR: 1.80; p  0.005), QRS duration 150 ms (OR: 1.79; p  0.007),
left bundle branch block (OR: 2.05; p  0.006), body mass index 30 kg/m2 (OR: 1.51; p  0.035), and
smaller baseline left atrial volume index (OR: 1.47; p  0.001). Cumulative probability of HF or all-cause death
at 2 years was 4% in super-responders, 11% in responders, and 26% in hypo-responders (log-rank p  0.001
overall). In multivariate analysis, hyporesponse was associated with increased risk of HF or all-cause death, com-
pared with super-response (hazard ratio: 5.25; 95% confidence interval: 2.01 to 13.74; p  0.001).
Conclusions Six baseline factors predicted LVEF super-response in CRT-D–treated patients with mild HF. Super-response was
associated with reduced risk of subsequent cardiac events. (Multicenter Automatic Defibrillator Implantation
Trial With Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271) (J Am Coll Cardiol 2012;59:
2366–73) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.065Biventricular pacing with cardiac resynchronization therapy
(CRT) and CRT with defibrillator (CRT-D) have been
shown to improve heart failure (HF) morbidity, quality of
life, and survival in those with reduced left ventricular
ejection fraction (LVEF), advanced HF symptoms, and
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June 19/26, 2012:2366–73 Predictors of Super-Response in the MADIT-CRT TrialHeart Association (NYHA) functional class or measures of left
ventricular remodeling (3,4). Overall, the average expected
improvement in absolute LVEF after CRT ranges from 3% to
5% (3,5).
There is wide variability in the extent of LV remodeling
and improvement in LVEF with CRT. Recent studies have
indicated that certain patients, referred to as “super-
responders,” may derive dramatic improvements, including
near normalization of LVEF (6,7). These and other studies
have identified patient characteristics associated with super-
response to CRT such as left bundle branch block (LBBB),
smaller LV and left atrial (LA) dimensions, greater LV strain,
shorter duration of HF symptoms, and nonischemic cardio-
myopathy (6–10). However, these relatively small studies
conducted follow-up echocardiographic assessment of LVEF
response at only 6 months post-implantation. Additionally, the
majority of patients had moderate to severe HF symptoms
(NYHA class III and IV), according to CRT implantation
guidelines in place at the time of these studies.
The MADIT-CRT (Multicenter Automatic Defibrilla-
tor Implantation Trial With Cardiac Resynchronization
Therapy) study recently showed that treatment with pro-
phylactic CRT-D reduced the risk of nonfatal HF or death
in patients with LVEF of 30%, QRS duration of 130
ms, and less severe HF symptoms (NYHA class I or II)
compared with patients receiving implantable cardioverter-
defibrillator (ICD) only (11). By assessing a large population
of patients undergoing CRT-D therapy with longer echocar-
diographic follow-up (at 12months) in this study, we sought to
define patient characteristics that predict LVEF super-
response to CRT in patients with mildly symptomatic (NYHA
class I and II) HF.We also sought to investigate an association
of LVEF super-response at 12 months with subsequent im-
provement in HF morbidity and survival.
Methods
Trial design. The MADIT-CRT design, study protocol,
and primary results have been published previously (11,12).
The trial enrolled 1,820 patients at 110 hospital centers
between December 22, 2004, and April 23, 2008. Patients
were randomly assigned in a 3:2 ratio to receive either
CRT-D or ICD. All patients provided informed consent,
including consent for echocardiographic analyses. The pro-
tocol was approved by the institutional review board at each
participating center. The trial enrolled patients of either sex
who were at least 21 years old with ischemic cardiomyop-
athy (NYHA class I or II) or nonischemic cardiomyopathy
(NYHA class II only), sinus rhythm, an ejection fraction of
30%, and prolonged intraventricular conduction with a
QRS duration of 130 ms. All patients met guideline
indications for ICD therapy. Additional details on inclusion
and exclusion criteria have been previously reported (11,12).
The primary analysis included Cox proportional hazards
regression for the outcome of nonfatal HF events or
all-cause mortality. pOur study population consisted of
752 patients (69%) randomized to
the CRT-D therapy group for
whomwehad complete information
regarding clinical and echocardio-
graphic data at baseline and at 12-
month follow-up examination (with
device on).
Echocardiographic methods.
Echocardiograms were obtained
according to the trial-specific
protocol at baseline before device
implantation (n  1,089 in
RT-D group) and at 12-month
ollow-up. The Food and Drug
dministration had originally re-
uested that follow-up echocar-
iography be performed with
RT turned off; however, after
he first 201 patients were tested
nder these conditions, the trial
rotocol was amended to allow
ollow-up echocardiography to
e performed with CRT turned on. Paired echocardiograms
rom both baseline and 12-month follow-up while the
evice was turned on were available in 752 (69%) of those
ssigned to CRT-D. Echocardiographic images and data
ere sent to the echocardiographic core laboratory at the
righam and Women’s Hospital, where quality assessment
as performed and LV, right ventricular, and LA measure-
ents were made in all baseline and 12-month follow-up
xaminations as previously described (13).
tudy design. Patients with paired echocardiograms were
ivided into quartiles of LVEF response based on change from
aseline to 12-month follow-up echocardiograms with device
n. Three groups based on response to CRT were defined and
abeled “super-responders,” “responders,” or “hypo-
esponders.” Super-response to CRT was defined by the
ighest quartile of LVEF change (n  191), response by the
econd and third quartiles of LVEF change (n  371), and
yporesponse by the lowest quartile of LVEF change (n 190).
The primary endpoint for clinical outcome of the study
as defined as nonfatal HF event or all-cause death,
hichever came first. HF event diagnoses were made by
hysicians who were aware of study assignments, and the
iagnoses required signs and symptoms consistent with HF
esponsive to intravenous decongestive therapy as an outpa-
ient or oral or intravenous medications administered during
hospitalization. The secondary endpoints were defined as:
) all-cause death; and 2) all-cause death or ICD therapy for
entricular tachycardia or ventricular fibrillation, whichever
ame first. Additional details on definitions of and therapy
or ventricular arrhythmias have been previously reported
14). Adjudication of endpoints was carried out by indepen-
ent committees unaware of study assignments, as described
Abbreviations
and Acronyms
BMI  body mass index
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
with defibrillator
HF  heart failure
ICD  implantable
cardioverter-defibrillator
LA  left atrial
LAVI  left atrial
volume index
LBBB  left bundle
branch block
LV  left ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationreviously (11,12).
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Predictors of Super-Response in the MADIT-CRT Trial June 19/26, 2012:2366–73In the first stage of analysis, we identified predictors
associated with LVEF super-response to CRT-D (with
responders and hypo-responders categorized together as the
reference group) among the 752 patients (69%) with avail-
able paired echocardiograms at baseline and at 12-month
follow-up. In the second stage of the analysis, we performed
a survival analysis of the primary and secondary endpoints
by LVEF response category. Subsequently, we included the
LVEF response variable in addition to all other variables to
identify the strongest predictors associated with the primary
endpoint of HF or all-cause death.
Statistical analysis. We included all clinical, electrocardio-
raphic, echocardiographic, and laboratory covariates as
otential predictors in the LVEF response category
odel. These baseline covariates were pre-specified for
ssessment in the design of the MADIT-CRT trial (12).
hresholds for categorization of numeric variables were
re-specified using accepted clinical and laboratory cri-
eria. In univariate analysis of covariates of interest and
VEF response category, continuous variables were an-
lyzed using the nonparametric Kruskal-Wallis test and
ategorical variables were analyzed using the chi-square
est. Multivariate logistic regression was used to deter-
ine predictors of super-response. The pool of variables
onsidered were those found to be significant at a pre-
pecified p  0.10 in univariate analysis. A best-subset
egression procedure was used to develop the model using
he best chi-square statistic for each given number of
ariables. The largest model that had at least 3.84 gain in
he chi-square score above the next smallest model was
hosen and then refit to ensure that all variables met the
ignificance level of 0.05.
For analysis of the association of LVEF response category
nd clinical outcomes, Kaplan-Meier estimates for nonfatal
F event or all-cause death (primary endpoint) as well as
ll-cause death (secondary endpoint) and all-cause death or
CD therapy for ventricular tachycardia or ventricular fibrilla-
ion (secondary endpoint) across echocardiographic response
ategories were determined and statistically evaluated with the
og-rank test. Cox proportional hazards regression analyses
ere performed to assess the predictors of the primary end-
oint (HF or all-cause death). A multivariate model for the
rimary endpoint was developed with Cox proportional haz-
rds regression using the same potential pool of covariates as
he multivariate logistic regression analysis discussed previ-
usly, with the addition of the LVEF response category
super-responder, responder, and hypo-responder). A best-
ubset regression method was used to build the model in the
ame manner as described, with a significance level set at 0.05.
likelihood ratio test was used to examine the added utility of
he 12-month echocardiographic LVEF response variable.
hecks for validity of the proportional hazards assumption
ere performed. All p values reported were 2-sided with a
re-specified significance at p  0.05. Analyses were per-
ormed with SAS software version 9.20 (SAS Institute Inc.,
ary, North Carolina). Iesults
uper-responders experienced a mean absolute LVEF in-
rease of 17.5  2.7%, with all super-responders improving
heir LVEF 14.5%; responders experienced a mean abso-
ute LVEF increase of 11.1 1.8% with an improvement of
VEF between 7.9% and 14.4%; hypo-responders experi-
nced a mean absolute LVEF increase of 4.4  3.2% with
n improvement in LVEF of 7.9%. Of 752 patients
ncluded in the cohort, 182 patients achieved a near nor-
alization of cardiac function, with an absolute LVEF45%
t 12months. A large proportion of super-responders (n 135
71%]) achieved an absolute LVEF 45% at 12 months,
ompared with a smaller proportion of responders (n  45
12%]) and hypo-responders (n  2 [1%]).
Table 1 presents baseline clinical, electrocardiographic,
chocardiographic, and laboratory characteristics of super-
esponders, responders, and hypo-responders. Super-
esponders were more often female, had nonischemic HF
tiology, had baseline LBBB, and had longer QRS duration
n electrocardiogram (ECG). Super-responders were less
pt to have had prior revascularization by coronary artery
ypass grafting or percutaneous coronary intervention, prior
yocardial infarction, prior smoking history, or prior ven-
ricular arrhythmia requiring treatment.
Echocardiographic changes of LVEF, LV end-diastolic
olume index, LV end-systolic volume index, and LA
olume index (LAVI) by responder group are shown in
able 2. For each echocardiographic measurement, there
ere significant differences across responder groups (p 
.001 for all comparisons). On average, super-responders
ad a 16.2  5.0 ml/m2 decrease in LAVI. There were less
xtreme decreases of LAVI in responders (13.3  5.0
l/m2) and hypo-responders (7.9  5.3 ml/m2). Changes
n chamber size and function within responder groups are
ummarized in Figure 1.
redictors of LVEF super-response to CRT-D. Best-
ubset regression analysis in patients with paired echocar-
iograms available at baseline and 12-month follow-up
dentified 6 predictors associated with LVEF super-
esponse to CRT-D therapy (Table 3). These predictors
ncluded female sex, no prior myocardial infarction, QRS
uration of 150 ms, LBBB on baseline ECG, body mass
ndex (BMI) 30 kg/m2, and smaller baseline LAVI (per 1
nit of SD below the mean). Best-subset regression analysis
o identify predictors associated with LV end-systolic vol-
me index response, as defined by a similar quartile cate-
orization used for LVEF, revealed that the same charac-
eristics were predictive of response.
linical outcomes. In our study population, the primary
ndpoint of nonfatal HF event or all-cause death after the
2-month follow-up echocardiogram occurred in 70 pa-
ients, with a median follow-up of 15.2 months. The
econdary endpoint of all-cause death occurred in 25 pa-
ients, and the secondary endpoint of all-cause death or
CD therapy for ventricular tachycardia or ventricular fibril-
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June 19/26, 2012:2366–73 Predictors of Super-Response in the MADIT-CRT TrialBaseline Clinical Characteristics of MADIT-CRT Patients WithP ir d Echocardiogr ms at Baseline and 12 Months by Responder CategoryTable 1 Baseline Clinical Characteristics of MADIT-CRT Pati nts WithPaired Echocardiograms at Baseline and 12 Months by Responder Category
Baseline Characteristics
Hypo-responder
(LVEF Change <7.9%)
(n  190)
Responder
(LVEF Change 7.9%–14.4%)
(n  371)
Super-Responder
(LVEF Change >14.5%)
(n  191) p Value
Age, yrs 63.6 11.8 64.9 10.5 64.2 10.5 0.401
Women 33 (17) 77 (21) 75 (39) 0.001
Race
White 167 (88) 341 (92) 177 (93) 0.138
Black 18 (9) 24 (6) 10 (5) 0.242
Body mass index 30 kg/m2 67 (36) 142 (39) 58 (31) 0.190
Enrolled from outside the
United States
69 (36) 133 (36) 48 (25) 0.022
Ischemic NYHA functional
class I
33 (17) 57 (15) 19 (10) 0.096
Ischemic NYHA functional
class II
97 (51) 151 (41) 55 (29) 0.001
Nonischemic NYHA functional
class II
60 (32) 163 (44) 117 (61) 0.001
Hypertension 120 (63) 241 (65) 115 (61) 0.586
Diabetes mellitus 54 (28) 118 (32) 45 (24) 0.117
Prior CABG surgery 71 (37) 103 (28) 36 (19) 0.001
Prior PCI 64 (34) 103 (28) 41 (22) 0.031
Prior myocardial infarction 108 (57) 161 (44) 50 (27) 0.001
Cerebrovascular accident 12 (6) 22 (6) 4 (2) 0.093
Previous cigarette smoking 104 (55) 215 (59) 90 (48) 0.050
Prior ventricular arrhythmias
requiring treatment
20 (11) 28 (8) 7 (4) 0.035
Creatinine 1.4 mg/dl 44 (23) 87 (24) 37 (19) 0.527
LBBB 106 (56) 263 (71) 165 (86) 0.001
RBBB 38 (20) 32 (9) 13 (7) 0.001
QRS duration, ms 153.9 18.1 159.7 20.8 160.9 17.4 0.001
QRS duration 150 ms 107 (56) 238 (64) 148 (77) 0.001
LVEDV index, ml/m2 122.5 25.5 126.4 27.0 124.0 24.7 0.215
LVESV index, ml/m2 85.9 20.3 90.2 21.9 87.6 20.6 0.064
LAV index, ml/m2 44.5 9.4 46.9 10.2 43.7 9.2 0.001
Aldosterone antagonists 57 (30) 121 (33) 61 (32) 0.819
Amiodarone 14 (7) 28 (8) 8 (4) 0.286
Angiotensin-converting
enzyme inhibitors
147 (77) 284 (77) 147 (77) 0.976
Angiotensin receptor blockers 39 (21) 82 (22) 37 (19) 0.740
Beta-blockers 173 (91) 348 (94) 185 (97) 0.061
Digitalis 57 (30) 96 (26) 47 (25) 0.446
Diuretics 136 (72) 262 (71) 120 (63) 0.109
Lipid-lowering statin drugs 131 (69) 270 (73) 109 (57) 0.001
Values are mean  SD or n (%).
CABG coronary artery bypass grafting; LAV left atrial volume; LBBB left bundle branch block; LVEDV left ventricular end-diastolic volume;LVESV  left ventricular end-systolic volume; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; PCI  percutaneous
coronary intervention; RBBB  right bundle branch block.Echocardiographic Parameters in Patients Who Underwent Baseline and12-Month Follow-Up Echocardiograms by Responder CategoryTable 2 Echo ardiographic Par m ters in Pati nts Wh Underwent Baseline and12-Month Follow-Up Echocardiograms by Responder Category
Hypo-responder (LVEF Change <7.9%) Responder (LVEF Change 7.9%–14.4%) Super-Responder (LVEF Change >14.5%)
N Baseline Change N Baseline Change N Baseline Change
LVEF, % 190 30.3 3.3 4.4 3.2 371 29.0 3.2 11.1 1.8 191 29.7 3.3 17.5 2.7
LVEDV index, ml/m2 187 122.5 25.5 11.2 10.1 367 126.4 27.0 26.5 11.8 188 124.0 24.7 40.8 16.8
LVESV index, ml/m2 187 85.9 20.3 12.6 10.7 367 90.2 21.9 29.8 10.0 188 87.6 20.6 43.1 13.4
LAV index, ml/m2 187 44.5 9.4 7.9 5.3 366 46.9 10.1 13.3 5.0 188 43.7 9.2 16.2 5.0Values are mean  SD.
Abbreviations as in Table 1.
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Predictors of Super-Response in the MADIT-CRT Trial June 19/26, 2012:2366–73lation occurred in 99 patients. The primary endpoint oc-
curred in 5 patients (2.6%) in the super-responder group, 29
patients (7.8%) in the responder group, and 36 patients
(19.0%) in the hypo-responder group. The secondary end-
point of all-cause death occurred in 3 patients (1.6%) in the
super-responder group, 10 patients (2.7%) in the responder
group, and 12 patients (6.3%) in the hypo-responder group.
The secondary endpoint of all-cause death or ICD therapy
for ventricular tachycardia or ventricular fibrillation oc-
curred in 10 patients (5.2%) in the super-responder group,
44 patients (11.9%) in the responder group, and 45 patients
(23.7%) in the hypo-responder group. The effect of LVEF
response to CRT-D and the cumulative probability of the
primary and secondary endpoints by Kaplan-Meier analysis
are shown in Figures 2A to 2C.
Figure 1 Changes in Echocardiographic Parameters in Super-R
Changes in mean echocardiographic variables between baseline and 12-month fol
LVEDVI  left ventricular end diastolic volume index; LVEF  left ventricular ejecti
Multivariate Analysis ofPred ctors of LVEF Super-ResponseTable 3 Multivariat Analysis ofPredictors of LVEF Super-Response
Variable Odds Ratio
95% Confidence
Interval p Value
Female 1.96 1.32–2.90 0.001
QRS duration 150 ms 1.79 1.17–2.73 0.007
LBBB 2.05 1.24–3.40 0.006
Body mass index 30 kg/m2 1.51 1.03–2.20 0.035
No prior myocardial infarction 1.80 1.20–2.71 0.005
Left atrial volume index, SD* 1.47 1.21–1.79 0.001a
*Per 1-U SD below mean.
Abbreviations as in Table 1.To estimate the linear relationship between the 3-level
LVEF response group and the primary endpoint of HF or
all-cause death, a univariate Cox proportional hazards
regression model with a single ordinal response group
measure was fit and revealed a trend of increasing LVEF
response group and lower hazard of the primary endpoint
(hazard ratio [HR]: 0.36 [referent: lower response group];
95% confidence intervals [CI]: 0.25 to 0.53; p  0.001 for
rend). A similar model for the all-cause mortality endpoint
as also estimated, with a similar trend seen of lower hazard
f the secondary endpoint with increasing LVEF response
roup (HR: 0.44 [referent: lower response group]; 95% CI:
.24 to 0.83; p  0.011 for trend). Finally, a model for the
econdary endpoint of all-cause death or ICD therapy for
entricular tachycardia or ventricular fibrillation was esti-
ated, and again, a similar trend of lower hazard of the
econdary endpoint with increasing LVEF response group
as seen (HR: 0.43 [referent: lower response group]; 95%
I: 0.32 to 0.59; p  0.001 for trend).
Including LVEF response category as a potential covari-
te, a best-subset regression procedure using Cox propor-
ional hazards multivariate regression was performed to
ssess predictors of the primary endpoint of HF or all-cause
eath (Table 4). Hyporesponse was associated with an
ncreased risk of HF or all-cause death as compared with
uper-response (HR: 5.25; 95% CI: 2.01 to 13.74; p 
.001). A baseline creatinine of 1.4 mg/dl was also
der, Responder, and Hypo-Responder Categories
among responder groups. LAVI  left atrial volume index;
tion; LVESVI  left ventricular end systolic volume index.espon
low-up
on fracssociated with an increased risk of the primary endpoint
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June 19/26, 2012:2366–73 Predictors of Super-Response in the MADIT-CRT Trial(HR: 3.02; 95% CI: 1.66 to 5.49; p  0.001), whereas
baseline LBBB was associated with a decreased risk of HF
or all-cause death (HR: 0.57; 95% CI: 0.34 to 0.94; p 
0.029). A likelihood ratio test was used to compare the fit of
the data with the addition of the LVEF response category
variable over the baseline model, which showed a significant
difference (p  0.001). Thus, adding the LVEF responder
variable to the baseline model significantly improved the
predictive power of the model.
Discussion
The present study, composed of patients with mildly symp-
tomatic HF in the MADIT-CRT study, identified specific
predictors of LVEF super-response to CRT-D and found
super-response to be associated with reduced risk of subse-
quent cardiac events (HF or all-cause death). We identified
6 baseline clinical, electrocardiographic, and echocardio-
graphic predictors of LVEF super-response in those as-
signed to CRT-D. These predictors included female sex, no
prior myocardial infarction, QRS duration150 ms, LBBB
on baseline ECG, BMI30 kg/m2, and smaller LAVI (per
1 unit of SD below the mean). The cumulative probability
of HF or all-cause death, all-cause death alone, and all-
cause death or ICD therapy for ventricular tachycardia or
ventricular fibrillation differed significantly across LVEF
response categories at 2 years of follow-up, with improved
event-free survival based on extent of response. When
LVEF response was included as a potential predictor of the
primary endpoint of HF or all-cause death in multivariate
analysis, LVEF hyporesponse (compared with super-
response) and a baseline creatinine of 1.4 mg/dl were
associated with an increased risk of subsequent HF or
all-cause death, whereas LBBB on baseline ECG was
associated with a decreased risk of HF or all-cause death.
These findings suggest that easily identifiable baseline
factors are associated with LVEF super-response on 12-
month follow-up echocardiogram in patients with mildly
symptomatic HF that meets other indications for CRT-D.
Further, LVEF response itself may predict subsequent
clinical outcomes, including HF or all-cause death.
LVEF is used to guide therapy and evaluate patient
response to HF treatments. Reduced LVEF is associated
Cox Proportional Hazards Regression Analysis ofPredictors of Nonfatal Heart Failure Event or DeathTable 4 Cox Proportional Hazards Regressi n Analysis ofPredictors of Nonfatal Heart Failure Event or Death
Variable*
Hazard
Ratio
95% Confidence
Interval p Value
LVEF response†
Super-responder Reference — —
Hypo-responder 5.25 2.01–13.74 0.001
Responder 2.24 0.86–5.83 0.099
LBBB 0.57 0.34–0.94 0.029
Creatinine 1.4 mg/dl 3.02 1.66–5.49 0.001
*Stratified by ischemic status. †The likelihood ratio test with 2 degrees of freedom testing theFigure 2
Kaplan-Meier Estimates of Cumulative Probability of
Heart Failure or Death, Death Alone, and Death or ICD
Therapy for VT or VF Stratified by Response Category
The 3 curves reflect the probability of outcome over time by response category in
cardiac resynchronization therapy with defibrillator patients with baseline and
12-month follow-up echocardiograms, after the 12-month follow-up echocardiogram
time point. (A) For the primary endpoint of heart failure or all-cause death, super-
responders (purple line) performed the best compared to responders (red line)
and hypo-responders (black line). (B) For the secondary endpoint of all-cause
death, super-responders (purple line) also did the best compared to responders
(red line) and hypo-responders (black line). (C) For the secondary endpoint of all-
cause death or ICD therapy for VT or VF, super-responders (purple line) again
fared the best compared to responders (red line) and hypo-responders (black
line). ICD  implantable cardioverter-defibrillator; HF  heart failure; VF  ventricu-
lar fibrillation; VT  ventricular tachycardia.responder and hypo-responder variables had a p value  0.001.
Abbreviations as in Table 1.
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Predictors of Super-Response in the MADIT-CRT Trial June 19/26, 2012:2366–73with risk of ventricular arrhythmia and sudden death; as a
result, randomized controlled trials and guidelines for pro-
phylactic defibrillator implantation to prevent sudden death
have relied heavily on this measurement (instead of volume
measurements, from which it is derived) to qualify for device
candidacy (15). Given the clinical reliance on LVEF as an
indication for therapy and for assessing response to CRT-D
therapy, we justified the classification of responsiveness to
CRT-D on the extent of improvement in ejection fraction
among patients enrolled in the MADIT-CRT trial. In our
study, super-responders, on average, experienced an 18
percentage point absolute improvement in LVEF.
LVEF is easily obtained, universally used by clinicians, and
associated with clinical outcomes, rendering it one of the most
widely used metrics to define response to CRT. However, the
heterogeneity in cardiac remodeling and clinical response in
patients who receive CRT-D therapy also highlights the need
to establish baseline factors to predict which patients will derive
the greatest benefit. Predicting super-response is important
given the findings of our study, which suggest that the extent
of improvement in LVEF at 12 months after CRT-D implan-
tation itself provides important prognostic information. LVEF
super-response at this time point is associated with a subse-
quent decreased cumulative probability of HF or all-cause
death, all-cause death alone, and ICD therapy for ventricular
tachycardia or ventricular fibrillation in a mildly symptomatic
HF population.
Our study of patients from the MADIT-CRT trial differs
from previous work evaluating clinical outcomes in super-
responders in that data were collected prospectively, at
multiple centers, and in a larger group of patients with HF
(10,16). Additionally, the MADIT-CRT study enrolled
patients with less severe HF (NYHA class I to II), whereas
previous studies included patients with more severe HF
(NYHA class III to IV). In our study, LVEF super-
response was defined at 12 months instead of 6 months,
which may have allowed more time for a true super-
responder effect to be realized. The findings of our study
suggest that LVEF can be used to define super-responders
to CRT-D therapy in a mildly symptomatic HF population,
and most importantly, that LVEF super-response is asso-
ciated with improved clinical outcomes by responder cate-
gory. The determinants of failure to respond to therapy and
the associated worse outcomes are likely based on a number
of variables that were not addressed in this study. Whether
more aggressive medical therapy, adjustment of CRT-D
parameters, or other adjunctive therapies will promote
additional reverse cardiac remodeling in hypo-responders at
12 months and beyond and whether these strategies im-
prove clinical outcomes are areas for future research.
In this study of patients assigned to CRT-D in the
MADIT-CRT cohort with available baseline and 12-
month follow-up echocardiograms, of the 6 predictors of
super-response identified, baseline LBBB (6,10) and smaller
LA volume (9) were previously identified as predictors of
LVEF super-response or hyper-response, but in mostlyadvanced HF populations (with NYHA class III and IV
symptoms). Female sex and prolonged QRS duration have
also been previously associated with overall improvement in
cardiac remodeling in other studies of CRT, but again
mostly in patients with advanced HF (17,18). Our findings
coincide with subsequent studies of the MADIT-CRT mild
HF population, which showed that women compared with
men (19) and patients with baseline LBBB compared with
non-LBBB (20) had improved echocardiographic parameters,
including LVEF in those assigned to CRT-D versus ICD.
However, our study further detailed the different levels of
LVEF response found in MADIT-CRT patients assigned to
CRT-D and identified other predictors of this response.
Lack of prior myocardial infarction predicted LVEF super-
response in our study. It is possible that the association of no
prior myocardial infarction and LVEF super-response is me-
diated by absence of LV scar, which was not specifically
investigated in the MADIT-CRT study. Previous studies on
the effect of scar and response to CRT have been contradictory
(21,22). Regardless of the mechanism, our study showed that
in multivariate analysis, absence of prior myocardial infarction
predicts LVEF super-response to CRT. That CRT response
in multivariate analysis was associated with lack of prior
myocardial infarction but not the etiology of cardiomyopathy
(ischemic vs. nonischemic) suggests possible confounding by
prior myocardial infarction in the relationship of cardiomyop-
athy etiology and CRT super-response.
We also found that BMI 30 kg/m2 predicted LVEF
super-response. To our knowledge, this is the first study to
associate a lower BMI with cardiac reverse remodeling
attributed to CRT-D therapy. Because BMI is a complex
variable composed of both height and weight, assessing its
association with LVEF response may prove difficult. For
example, human weight composition varies person to person
and can be influenced by lean body mass, adiposity, and
volume overload, particularly in an HF population. Addi-
tionally, our findings contrast with previous studies report-
ing an “obesity paradox” of BMI and HF outcomes, such
that higher BMI was associated with improved HF out-
comes (23). We found that lower BMI was associated with
LVEF super-response, which itself was associated with
improved clinical outcomes. Future studies of response to
CRT-D therapy should focus on the determinants of BMI
and associations with cardiac remodeling. In addition,
whether a lower BMI predicts LVEF response to CRT-D
is specific to a mildly symptomatic HF population, such as
the one studied in the MADIT-CRT trial, is unknown and
deserves further investigation.
Study limitations. The study protocol of follow-up echo-
cardiograms obtained at 12 months rendered us unable to
determine the timing of improvement in LVEF before 1
year. As a result, we were unable to determine if the rapidity
with which ejection fraction improved was associated with
clinical outcome. We were also unable to assess predictors of
delayed improvement of LVEF and outcomes associated
with late improvement. Additionally, the short duration of
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the present analysis. After the 12-month echocardiogram,
which categorized patients into LVEF responder groups,
the average follow-up time was 15.2 months. Given the
brief follow-up time and the small number of events, longer
follow-up is warranted. Assignment to CRT-D response
category was dependent on echocardiographic measurement
of LV volumes and calculation of LVEF. The high level of
reproducibility in measuring LVEF in our study may not be
as precise in other clinical settings and may reduce the
generalizability of these results. Finally, our study focused
intentionally on patients assigned to CRT-D therapy, with
baseline and 12-month follow-up echocardiograms. There-
fore, patients who died or were lost to follow-up before the
12-month echocardiogram were not included in our analy-
sis. Although there were few patients who were lost to
follow-up or died in the first 12 months, it is possible that
selection bias may have been introduced (i.e., patients with
lower LVEF or no response may have been more likely to
die or be lost to follow-up for the 12-month echocardio-
gram, therefore selecting for a super-response group less
likely to experience subsequent HF or death).
Conclusions
Findings from the MADIT-CRT trial suggested that
LVEF super-response at 12-month follow-up echocardio-
gram was associated with improved HF event-free survival
after 2 years in CRT-D patients with mild HF symptoms.
In this same patient population, female sex, no prior
myocardial infarction, QRS duration of 150 ms, LBBB,
BMI of 30 kg/m2, and smaller baseline LAVI predicted
LVEF super-response to CRT-D. Our observations suggest
that certain baseline factors may predict LVEF super-
response for this population and that LVEF super-
responders may enjoy freedom from subsequent HF or
all-cause death, even for those with mild HF symptoms at
the time of CRT-D implantation.
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